Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma
In conclusion, TACC2 is an important regulator of the immune response in STS, functioning as a tumor suppressor and a modulator of response to PD-1 blockade. Its role in modulating chemokine expression and CD8 + T cell infiltration highlights its potential as a therapeutic target and predictive biomarker for STS immunotherapy.
Authors
- Tianliang Xia (ORCID: https://orcid.org/0009-0002-3369-8612)
- Liyuan Le
- Xiuxia Lu (ORCID: https://orcid.org/0000-0002-1620-197X)
- Qiyan Cai
- Dong‐Chun Hong (ORCID: https://orcid.org/0000-0003-1892-9806)
- Mengmeng Liu (ORCID: https://orcid.org/0000-0002-0432-9386)
- Xing Zhang (ORCID: https://orcid.org/0000-0001-7101-7182)
- Jing Yang (ORCID: https://orcid.org/0000-0001-6612-7854)
- Xinke Zhang (ORCID: https://orcid.org/0000-0002-3527-2140)
Institutions
- Sun Yat-sen University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Jiangxi Provincial Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1186/s12943-025-02354-2
- Citations
- 6
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.11
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China